Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Albireo, an Ipsen Company
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05642468CT.gov Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Sclerosing Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ritivixibat (this asset) | Albireo, an Ipsen Company | P2 | CCC · 53 |
| Vancomycin | Tampere University Hospital | P4 | BB |
| Ursodeoxycholic Acid | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Elafibranor | Ipsen | P3 | B |
| Aldafermin | NGM Biopharmaceuticals, Inc | P2/3 | B |
| CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY | ChemomAb Ltd. | P2 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
| Tretinoin | Yale University | P2 | B |
| Cilofexor | Gilead Sciences | P3 | B |
+42 more in the Primary Sclerosing Cholangitis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ritivixibat in Primary Sclerosing Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ritivixibat-primary-sclerosing-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →